Automated TCR-T production streamlines personalized immunotherapy, reducing patient burden and improving engineered T cell quality.
On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...
This year will be regarded as an inflection point for the treatment of glioblastoma, a rare and aggressive form of brain cancer that carries a median survival time of around 15 to 18 months, said Carl ...
DUBLIN--(BUSINESS WIRE)--The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2024" report has been added to ResearchAndMarkets.com's offering. CAR-T cell therapy is a ...
Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...
MSK cellular therapist Dr. Heather Landau led a phase 1 clinical trial showing CAR T cell therapy is effective against relapsed or resistant AL amyloidosis. “I’ve seen very sick patients have an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback